The Medical Advisor

An evidence‑aware guide to off‑label cancer therapies, integrative oncology, precision oncology and emerging research — without hype or false promises. This page serves as the central hub for OneDayMD’s coverage of repurposed drugs and precision oncology in cancer care, integrating conventional oncology standards with systems biology, real‑world data, and ethical analysi s. What This Hub Covers (Quick Overview) This hub explains: What repurposed drugs are — and what they are not. Which drugs show credible anti‑cancer signals vs speculation. How repurposed therapies may (or may not) integrate with standard oncology. The evidence hierarchy used across OneDayMD. Safety, ethics, and regulatory realities. It is designed for patients, clinicians, and researchers seeking clarity rather than promotion . Diverse cancer hallmarks targeted by repurposed non-oncology drugs. This figure was created with Biorender.com. Source:  Nature 2024 Executive Summary Repurposed drugs in cancer care ref...

Once deemed "undruggable" due to its smooth surface and high affinity for GTP, the KRAS oncogene has become a prime target in precision oncology. KRAS mutations drive approximately 20-30% of all cancers, with high prevalence in non-small cell lung cancer (NSCLC, ~30%), colorectal cancer (CRC, ~40%), and pancreatic ductal adenocarcinoma (PDAC, >90%). The most common mutation historically was G12C, but breakthroughs now extend to G12D, G12V, and multi-selective "pan-KRAS" approaches. Update: KRAS Inhibitors: Targeting the 'Undruggable' Mutation in 2026 and Beyond Key Breakthroughs in KRAS G12C Inhibitors The pioneering covalent inhibitors sotorasib (Lumakras) and adagrasib (Krazati), approved earlier for KRAS G12C-mutated NSCLC, saw major expansions in 2025: January 2025 FDA approval : Sotorasib combined with panitumumab (Vectibix, an EGFR inhibitor) for previously treated KRAS G12C-mutated metastatic CRC. This combination addresses adaptive resistance via ...